

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office on the date shown below:

AMENDMENT UNDER 37 CFR 1.111
Examining Group 1609
Patent Application
Docket No. GJE-7147

January 31, 2008 :

David Saliwanchik
David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Sahar Javanmard
Art Unit : 1609
Applicants : Robin Mark Bannister *et al.*
Serial No. : 10/517,881
Filed : December 13, 2004
Conf. No. : 1605
For : Use of Nefopam for the Treatment of Nausea or Emesis

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA. 22313-1450

SUPPLEMENTAL AMENDMENT UNDER 37 CFR §1.111

Sir:

This Supplemental Amendment is being submitted to the Patent Office further to the Amendment dated December 20, 2007 that was submitted to the Patent Office in response to the Office Action dated July 25, 2007, please amend the above-referenced application as follows:

Amendments to the Claims are reflected in the listing of claims beginning on page 2 of this paper.

Remarks/Arguments follow the amendment section of this paper.